Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Adaptimmune Therapeutics PLC incurred credit facility of up to $125.0 million with Hercules Capital, Inc. at an annual rate equal to the greater of (i) 9.65% or (ii) 1.15% plus the Wall Str maturing June 1, 2029.
- Instrument
- credit facility
- Principal
- up to $125.0 million
- Counterparty
- Hercules Capital, Inc.
- Rate
- an annual rate equal to the greater of (i) 9.65% or (ii) 1.15% plus the Wall Str
- Maturity
- June 1, 2029
- Event
- incurrence
Exact text from the filing
On May 14, 2024 (the “Closing Date”), Adaptimmune Therapeutics plc (the “Company” and collectively with any Company affiliates that are made party to the Loan Agreement, “Borrower”) entered into a Loan and Security Agreement (the “Loan Agreement”), with several banks and other financial institutions or entities from time to time party hereto as lenders (each, a “Lender”, and collectively “Lenders”) and Hercules Capital, Inc., a Maryland corporation in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, including any successors or assigns, the “Agent”), for a term loan facility of up to $125.0 million (the “Term Loan”), consisting of a term loan advance in the aggregate principal amount equal to $25.0 million on the Closing Date (the “Tranche 1 Advance”), a term loan advance available to the Company subject to certain terms and conditions in the aggregate principal amount of $25.0 million (the “Tranche 2 Advance’), a term loan advance
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Adaptimmune Therapeutics PLC entered into Loan and Security Agreement with Hercules Capital, Inc. valued at up to $125,000,000 term loan facility (effective 2024-05-14).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc.
- Value
- up to $125,000,000 term loan facility
- Effective
- 2024-05-14
Exact text from the filing
On May 14, 2024 (the “Closing Date”), Adaptimmune Therapeutics plc (the “Company” and collectively with any Company affiliates that are made party to the Loan Agreement, “Borrower”) entered into a Loan and Security Agreement (the “Loan Agreement”), with several banks and other financial institutions or entities from time to time party hereto as lenders (each, a “Lender”, and collectively “Lenders”) and Hercules Capital, Inc., a Maryland corporation in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, including any successors or assigns, the “Agent”), for a term loan facility of up to $125.0 million (the “Term Loan”), consisting of a term loan advance in the aggregate principal amount equal to $25.0 million on the Closing Date (the “Tranche 1 Advance”), a term loan advance available to the Company subject to certain terms and conditions in the aggregate principal amount of $25.0 million (the “Tranche 2 Advance’), a term loan advance
View on SEC.gov